Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
| Revenue (Most Recent Fiscal Year) | $36.13M |
| Net Income (Most Recent Fiscal Year) | $-215.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 90.50 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -670.59% |
| Net Margin (Trailing 12 Months) | -685.64% |
| Return on Equity (Trailing 12 Months) | -50.28% |
| Return on Assets (Trailing 12 Months) | -42.00% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.23 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 75.63M |
| Free Float | 72.84M |
| Market Capitalization | $5.09B |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 1.09 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |